Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models

BACKGROUND: Uncontrolled immune response with T cell activation has a key role in the pathogenesis of systemic sclerosis (SSc), a disorder that is characterized by generalized fibrosis affecting particularly the lungs and skin. Costimulatory molecules are key players during immune activation, and re...

Descripción completa

Detalles Bibliográficos
Autores principales: Orvain, Cindy, Cauvet, Anne, Prudent, Alexis, Guignabert, Christophe, Thuillet, Raphaël, Ottaviani, Mina, Tu, Ly, Duhalde, Fanny, Nicco, Carole, Batteux, Frédéric, Avouac, Jérôme, Wang, NingXin, Seaberg, Michelle A., Dillon, Stacey R., Allanore, Yannick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728910/
https://www.ncbi.nlm.nih.gov/pubmed/34986869
http://dx.doi.org/10.1186/s13075-021-02709-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728910/
https://www.ncbi.nlm.nih.gov/pubmed/34986869
http://dx.doi.org/10.1186/s13075-021-02709-2

Ejemplares similares